New Website for Cancer Pain Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

NEW YORK-The Association of Cancer Online Resources (ACOR) has launched a new website, Cancer-pain.org, to provide cancer patients with the education and support they need to obtain effective pain relief.

NEW YORK—The Association of Cancer Online Resources (ACOR) has launched a new website, Cancer-pain.org, to provide cancer patients with the education and support they need to obtain effective pain relief.

The site features sections on the causes of pain, breakthrough pain, pain treatment options, and tools to help cancer patients communicate effectively with physicians about their pain. It also has a complete list of medications available to treat pain, information about complementary and alternative methods of pain control, and a section devoted to the special needs and issues of caregivers. The website is supported through an educational grant from Cephalon, Inc.

Articles in this issue
Adjuvant Chemo Dose Reductions Frequent in Breast Cancer
Women May Be at Greater Risk for Undertreatment of Cancer Pain
Umbilical Cord Blood in Adult Leukemia Patients
Irinotecan Results Continue to Be Encouraging in Colorectal Cancer
Irinotecan Active in Pediatric Cancers
Combined Modality Therapy Has Enhanced Activity in Locally Advanced Rectal Cancer
Ultrasound Contrast Agents Help Diagnose Prostate Cancer
Optimal Use of Irinotecan Still to be Determined
Groups Urge Federal Action Against Eclipse Cigarettes
Potential Advantages of Oral Irinotecan Defined in Phase I Studies
New Website for Cancer Pain Patients
Creative Center for Women With Cancer Adds the Performing Arts
More Precise Surrogate Markers for Clinical Response Are Needed
Rubitecan Appears Active in Advanced Pancreatic Cancer
Physicians Must Unite Against New Bureaucratic ‘Hassles’ to Practicing Medicine
Recent Videos
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

Tim Cortese
November 20th 2024
Article

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.